RxSight, Inc. is a commercial-stage medical technology company focused on ophthalmic devices for cataract surgery. The company develops and sells the RxSight Light Adjustable Lens system, which consists of the Light Adjustable Lens (LAL) intraocular lens and the Light Delivery Device (LDD). This system allows surgeons to customize and optimize patient visual acuity after surgery using ultraviolet light to adjust the lens's refractive power. RxSight serves the premium cataract surgery market, primarily in the United States, where it operates a direct sales model targeting ophthalmology practices and cataract surgeons. The company’s products are designed to address limitations of conventional fixed-power premium intraocular lenses by enabling post-surgical adjustments to spherical and cylindrical refraction. Commercial operations began in 2019, and the company continues to expand its installed base of Light Delivery Devices and drive utilization of its lenses through clinical specialists and field service support.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Medical Devices Homepage rxsight.com
Sector Healthcare IR page investors.rxsight.com
Tags
ophthalmology, cataract surgery, intraocular lenses, premium iols, vision correction, medical technology, RxSight Light Adjustable Lens system, RxSight Light Adjustable Lens, LAL, LAL+, RxSight Light Delivery Device, LDD
Press page —

Metrics

Valuation  
Market cap $ 205.443M
Market cap (USD) $ 205.443M
P/E -3.83
PEG —
P/BV 0.81
P/S 1.78
P/OCF 8.68
P/FCF 11.02
Dividend yield —
Turnover / mcap —
Returns  
ROE -14.0%
ROI -15.2%
ROIC -14.1%
Profit margin -29.0%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 5
Quality score -62.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue 134.479M 139.927M 89.077M 49.005M 22.593M 0
Net profit -38.944M -27.455M -48.608M -66.756M -48.688M 0
Free cash flow -19.341M -22.386M -46.407M -61.243M -46.648M —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Share price 10.42 34.38 40.32 12.67 11.25 —
Price performance 12m -0.7 -0.15 2.18 0.13 — —

Filed figures

Figure Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — 2.87M 4.86M 11M 20.3M 30.1M 23.4M
↳ YoY growth +69.7% +125.3% +85.1% +48.2% -22.2%
↳ 5y CAGR +52.2%
Lease liabilities (USD) — 6.35M 5.17M 4.83M 3.01M 12.3M 11M
Cash and deposits (USD) 8.83M 14M 24.4M 11.8M 9.69M 16.7M 19.9M
Right-of-use assets (USD) — 5.32M 4.28M 3.94M 2.44M 11.2M 9.96M
Cash flow detail
Operating cash flow (USD) — -35.2M -44.7M -58.9M -41.6M -16.9M -15.5M
Purchases of property, plant and equipment (USD) — -2.54M -1.94M -2.39M -4.81M -5.44M -3.83M
Change in receivables (cash effect) (USD) — -2.08M -2M -6.09M -9.33M -9.8M 6.66M
Change in inventories (cash effect) (USD) — -1.31M -2.11M -7.56M -2.75M -4.99M -11.5M
Change in payables (cash effect) (USD) — -954,000 555,000 635,000 1.25M 946,000 627,000
Income taxes paid (cash effect) (USD) — -61,000 -20,000 -3,000 -8,000 -24,000 -58,000
Share-based compensation (USD) — 4.19M 7.58M 11.4M 15.7M 24.6M 31.6M
Operating cash flow before change in receivables (USD) — -33.1M -42.7M -52.8M -32.3M -7.14M -22.2M
Free cash flow (OCF - PPE - intangibles) (USD) — -37.7M -46.6M -61.2M -46.4M -22.4M -19.3M
Income detail
Research and development expense (USD) — 21.9M 24.5M 26M 29.1M 34.4M 38.5M
↳ 5y CAGR +11.9%
Total comprehensive income (USD) — 27.5M -48.7M -66.8M -48.5M -27.3M -39.1M
Comprehensive income to owners (USD) — 27.5M -48.7M -66.8M -48.5M -27.3M -39.1M
Provision for credit losses (USD) — 0.00 0.00 0.00 0.00 0.00 0.00
Credit cost ratio (credit losses / average receivables) (%) — — 0.0% 0.0% 0.0% 0.0% 0.0%
Reported Sep 9, 2021 Mar 8, 2022 Mar 8, 2022 Mar 6, 2023 Feb 28, 2024 Feb 25, 2025 Feb 25, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

RxSight, Inc. Reports Third Quarter 2026 Results Bull 2 Bear 4 Results

Nov 03, 2026

Download PDF

ALISO VIEJO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today reported financial results for the quarter ended September 30, 2026.

Third Quarter 2026 Financial Highlights

  • Total revenue of $24.6 million primarily driven by 23,128 Light Adjustable Lens™ (LAL™) units

  • Cash, cash equivalents and short-term investments of $254.7 million as of September 30, 2026, including the $60 million received in the third quarter in connection with the Alcon collaboration

Strategic Highlights

The company highlighted the following recent strategic developments:

  • Strengthened commercial leadership with the appointments of experienced eye care leaders Taryn Conway as Chief Commercial Officer and Frank Shields as EVP of Sales and Commercial Strategy

  • Advancing U.S. commercial transformation, including nearly doubling its sales force to support deeper customer engagement and enhanced practice support

  • Completed significant organizational restructuring to better align resources with strategic priorities and drive meaningful operating expense savings in the core business

  • Advancing the Alcon collaboration, with the partnership off to a strong start and the initial 120-day period under the agreement now complete

“Since I joined last quarter, the team has moved quickly and accomplished a great deal in a short period of time,” said Aziz Mottiwala, President and Chief Executive Officer of RxSight. “We have strengthened our commercial organization and leadership, made progress across key long-term growth initiatives, and taken decisive actions to align our cost structure with our priorities. While there is more work ahead, we remain focused on execution. Based on our progress, I am confident we are positioning our company for long-term success.”

Third Quarter Financial Results

In the third quarter of 2026, total revenue was $24.6 million, down 19% from the prior-year period, primarily reflecting ongoing competitive pressures. Consistent with the early stages of the program, revenue recognized under the company’s strategic collaboration with Alcon was minimal during the quarter.

Third-quarter gross margin was 73.6%, compared with 79.9% in the prior-year period, primarily reflecting an increase in inventory reserves and higher inventory costs for LAL and LDD, partially offset by favorable product mix. The Alcon collaboration had an immaterial impact on gross margin during the quarter.

Total cost and expenses for the third quarter of 2026 were $43.1 million relatively consistent versus $42.5 million in the year-ago period.

In the third quarter, the company reported a net loss of $(16.2) million, or $(0.39) per basic and diluted share, compared to a net loss of $(9.8) million, or $(0.24) per basic and diluted share in the third quarter of 2025. Adjusted net loss in the third quarter of 2026 was $(8.6) million, or $(0.21) per basic and diluted share, compared to an adjusted net loss of $(1.7) million, or $(0.04) per basic and diluted share in the third quarter of 2025.

As of September 30, 2026, cash, cash equivalents and short-term investments totaled $254.7 million, including the $60 million received in the third quarter in connection with the Alcon collaboration.

Conference Call

On Tuesday, November 3, 2026, at 1:30 p.m. Pacific Time, the company will host a conference call to discuss its third quarter 2026 financial results. To participate in the conference call, please dial (800) 715-9871 or (646) 307-1963 and enter the conference code: 8782462. The call will also be broadcast live in listen-only mode via a link on the company’s investor relations website at https://investors.rxsight.com/. An archived recording of the call will be available through the same link shortly after its completion.

About RxSight, Inc.

RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The Light Adjustable Lens™ system, comprised of the RxSight Light Adjustable Lens™ products (LAL™ and LAL+™), RxSight Light Delivery Device™ (LDD™), and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.

Forward-Looking Statements

This press release contains forward-looking statements, including, without limitations, statements regarding the company’s business, strategies and prospects and positioning for long-term success. Such statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "projects," "potential," or "continue" or the negative of such terms and other similar terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors, including the risk factors that may be found in the section entitled Part II, Item 1A (Risk Factors) in the company’s Quarterly Report on Form 10-Q for the three months ended September 30, 2026, filed with the Securities and Exchange Commission (SEC) on or about the date hereof, and the other documents that RxSight may file from time to time with the SEC. These and other factors may cause our actual results to differ materially from any forward-looking statement. RxSight undertakes no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.

RxSight, Inc., the RxSight Light Adjustable Lens Technology, LAL, LAL+, and LDD are trademarks of RxSight, Inc.

Investor Relations Contact:

Oliver Moravcevic

VP, Investor Relations

[email protected]

| RxSIGHT, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) (In thousands, except share and per share amounts) |

| | | | | | | | | | | | | |

| | | Three Months Ended September 30, | | | Nine Months Ended September 30, | |

| | | 2026 | | | 2025 | | | 2026 | | | 2025 | |

| Revenue: | | | | | | | | | | | | |

| Product sales | | $ | 24,546 | | | $ | 30,340 | | | $ | 82,680 | | | $ | 101,871 | |

| License and collaboration revenue | | | 40 | | | | — | | | | 6,540 | | | | — | |

| Total revenue | | | 24,586 | | | | 30,340 | | | | 89,220 | | | | 101,871 | |

| Costs and expenses: | | | | | | | | | | | | |

| Cost of sales | | | 6,487 | | | | 6,113 | | | | 21,738 | | | | 24,125 | |

| Selling, general and administrative | | | 27,404 | | | | 27,345 | | | | 89,678 | | | | 84,956 | |

| Research and development | | | 9,213 | | | | 9,060 | | | | 27,922 | | | | 29,644 | |

| Total costs and expenses | | | 43,104 | | | | 42,518 | | | | 139,338 | | | | 138,725 | |

| Loss from operations | | | (18,518 | ) | | | (12,178 | ) | | | (50,118 | ) | | | (36,854 | ) |

| Other income (expense), net: | | | | | | | | | | | | |

| Interest expense | | | (3 | ) | | | (4 | ) | | | (9 | ) | | | (14 | ) |

| Interest and other income | | | 2,325 | | | | 2,376 | | | | 6,043 | | | | 7,137 | |

| Loss before income taxes | | | (16,196 | ) | | | (9,806 | ) | | | (44,084 | ) | | | (29,731 | ) |

| Income tax expense | | | 28 | | | | 10 | | | | 122 | | | | 61 | |

| Net loss | | $ | (16,224 | ) | | $ | (9,816 | ) | | $ | (44,206 | ) | | $ | (29,792 | ) |

| Other comprehensive (loss) gain: | | | | | | | | | | | | |

| Unrealized (loss) gain on short-term investments | | | (59 | ) | | | 178 | | | | (184 | ) | | | (123 | ) |

| Foreign currency translation gain (loss) | | | 18 | | | | (1 | ) | | | 31 | | | | 18 | |

| Total other comprehensive (loss) gain | | | (41 | ) | | | 177 | | | | (153 | ) | | | (105 | ) |

| Comprehensive loss | | $ | (16,265 | ) | | $ | (9,639 | ) | | $ | (44,359 | ) | | $ | (29,897 | ) |

| | | | | | | | | | | | | |

| Net loss per share: | | | | | | | | | | | | |

| Basic & diluted | | $ | (0.39 | ) | | $ | (0.24 | ) | | $ | (1.07 | ) | | $ | (0.73 | ) |

| Weighted-average shares used in computing net loss per share: | | | | | | | | | | | | |

| Attributable to common stock, basic & diluted | | | 41,705,436 | | | | 40,965,219 | | | | 41,502,275 | | | | 40,741,219 | |

| | | | | | |

| |

| |

| |

| RxSIGHT, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except share and per share amounts) |

| |

| | | | | | |

| | September 30, | | | December 31, | |

| | 2026 | | | 2025 | |

| | (Unaudited) | | | | |

| Assets | | | | | |

| Current assets: | | | | | |

| Cash and cash equivalents | $ | 66,717 | | | $ | 19,949 | |

| Short-term investments | | 187,966 | | | | 208,179 | |

| Accounts receivable, net | | 16,998 | | | | 23,383 | |

| Inventories | | 39,593 | | | | 31,559 | |

| Prepaid and other current assets | | 3,530 | | | | 4,389 | |

| Total current assets | | 314,804 | | | | 287,459 | |

| Property and equipment, net | | 14,649 | | | | 13,056 | |

| Operating leases right-of-use assets | | 9,246 | | | | 9,959 | |

| Restricted cash | | 750 | | | | 750 | |

| Other assets | | 969 | | | | 590 | |

| Total assets | $ | 340,418 | | | $ | 311,814 | |

| Liabilities and stockholders' equity | | | | | |

| Current liabilities: | | | | | |

| Accounts payable | $ | 3,423 | | | $ | 5,296 | |

| Accrued expenses and other current liabilities | | 15,189 | | | | 16,274 | |

| Deferred revenue, current | | 4,496 | | | | 3,521 | |

| Lease liabilities | | 1,844 | | | | 1,162 | |

| Refund liability | | 50,000 | | | | — | |

| Total current liabilities | | 74,952 | | | | 26,253 | |

| Long-term lease liabilities | | 8,476 | | | | 9,878 | |

| Deferred revenue, noncurrent | | 2,079 | | | | — | |

| Total liabilities | | 85,507 | | | | 36,131 | |

| Stockholders' equity: | | | | | |

| Common stock, $0.001 par value, 900,000,000 shares authorized, 41,927,222 shares issued and outstanding as of September 30, 2026 and 41,242,005 shares issued and outstanding as of December 31, 2025 | | 42 | | | | 41 | |

| Preferred stock, $0.001 par value, 100,000,000 shares authorized, no shares issued and outstanding as of September 30, 2026 and December 31, 2025 | | — | | | | — | |

| Additional paid-in capital | | 960,213 | | | | 936,628 | |

| Accumulated other comprehensive (loss) income | | (100 | ) | | | 53 | |

| Accumulated deficit | | (705,244 | ) | | | (661,039 | ) |

| Total stockholders' equity | | 254,911 | | | | 275,683 | |

| Total liabilities and stockholders' equity | $ | 340,418 | | | $ | 311,814 | |

Supplemental Information on Gross Margin

A reconciliation of gross margin and gross margin percentage to revenues and cost of sales for the three months ended September 30, 2026 and 2025 are as follows:

| | Three Months Ended September 30, | | | Three Months Ended September 30, | |

| | 2026 | | | 2025 | |

| Gross Margin | Product | | Collaboration | | Total | | | Product | | Collaboration | | Total | |

| Sales | $ | 24,546 | | $ | 40 | | $ | 24,586 | | | $ | 30,340 | | $ | — | | $ | 30,340 | |

| Cost of sales | | 6,487 | | | — | | | 6,487 | | | | 6,113 | | | — | | | 6,113 | |

| Gross profit | $ | 18,059 | | $ | 40 | | $ | 18,099 | | | $ | 24,227 | | $ | — | | $ | 24,227 | |

| Gross margin % | | 73.6 | % | | 100.0 | % | | 73.6 | % | | | 79.9 | % | | 0.0 | % | | 79.9 | % |

A reconciliation of gross margin and gross margin percentage to revenues and cost of sales for the nine months ended September 30, 2026 and 2025 are as follows:

| | Nine Months Ended September 30, | | | Nine Months Ended September 30, | |

| | 2026 | | | 2025 | |

| Gross Margin | Product | | Collaboration | | Total | | | Product | | Collaboration | | Total | |

| Sales | $ | 82,680 | | $ | 6,540 | | $ | 89,220 | | | $ | 101,871 | | $ | — | | $ | 101,871 | |

| Cost of sales | | 21,738 | | | — | | | 21,738 | | | | 24,125 | | | — | | | 24,125 | |

| Gross profit | $ | 60,942 | | $ | 6,540 | | $ | 67,482 | | | $ | 77,746 | | $ | — | | $ | 77,746 | |

| Gross margin % | | 73.7 | % | | 100.0 | % | | 75.6 | % | | | 76.3 | % | | 0.0 | % | | 76.3 | % |

Non-GAAP Financial Measures

To supplement our unaudited condensed consolidated financial statements presented under generally accepted accounting principles in the United States (“GAAP”), we believe certain non-GAAP measures, including adjusted net loss, and adjusted net loss per share, basic and diluted, provide useful information to investors and are useful in evaluating our operating performance. For example, we exclude stock-based compensation expense because this expense is non-cash in nature and we believe excluding this item provides meaningful supplemental information regarding our operational performance and allows investors the ability to make more meaningful comparisons between our operating results and those of other companies.

We believe that non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. In addition, other companies, including companies in our industry, may calculate similarly titled non-GAAP measures differently or may use other measures to evaluate their performance. A reconciliation is provided below for each non-GAAP financial measure to the most directly comparable financial measure stated in accordance with GAAP. Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures, and not to rely on any single financial measure to evaluate our business.

Adjusted Net Loss and Adjusted Net Loss Per Share

Adjusted net loss is a non-GAAP financial measure that we define as net loss adjusted for stock-based compensation. We believe adjusted net loss provides investors with useful information on period-to-period performance as evaluated by management and comparison with our past financial performance and is useful in evaluating our operating performance compared to that of other companies in our industry, as this metric generally eliminates the effects of certain items that may vary from company to company for reasons unrelated to overall operating performance.

A reconciliation of net loss to adjusted net loss and the presentation of adjusted net loss per share, basic and diluted, are as follows:

| | | Three months ended September 30, | | | Nine months ended September 30, | |

| | | 2026 | | | 2025 | | | 2026 | | | 2025 | |

| Common Stock | | | | | | | | | | | | |

| Numerator: | | | | | | | | | | | | |

| Net loss available to stockholders, basic and diluted | | $ | (16,224 | ) | | $ | (9,816 | ) | | $ | (44,206 | ) | | $ | (29,792 | ) |

| Add: | | | | | | | | | | | | |

| Stock-based compensation | | | 7,634 | | | | 8,108 | | | | 23,044 | | | | 23,795 | |

| Adjusted net loss available to common stockholders, basic and diluted: | | $ | (8,590 | ) | | $ | (1,708 | ) | | $ | (21,162 | ) | | $ | (5,997 | ) |

| | | | | | | | | | | | | |

| Denominator: | | | | | | | | | | | | |

| Weighted-average shares outstanding, basic and diluted | | | 41,705,436 | | | | 40,965,219 | | | | 41,502,275 | | | | 40,741,219 | |

| Adjusted net loss per share, basic and diluted | | $ | (0.21 | ) | | $ | (0.04 | ) | | $ | (0.51 | ) | | $ | (0.15 | ) |

Oct 23, 2026

Download PDF

ALISO VIEJO, Calif., Oct. 23, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced that on October 23, 2026, RxSight granted inducement stock options to purchase a total of 236,456 shares of RxSight’s common stock to two new non-executive officer employees in connection with the commencement of their employment with RxSight. RxSight also agreed to grant inducement restricted stock units (RSUs) covering a total of 637,449 shares of RxSight’s common stock to the same employees in connection with the commencement of their employment with RxSight, which RSUs are anticipated to be granted on or about November 3, 2026.

Each inducement stock option has an exercise price of $5.02 per share, which is equal to the closing price of a share of RxSight common stock on the grant date, and shall vest as follows, subject to continuing service: 25% of the shares subject to such inducement stock option shall vest on the one year anniversary of October 23, 2026, and one forty-eighth (1/48th) of the shares subject to such inducement stock option shall vest monthly thereafter.

Each inducement RSU award shall vest as follows, subject to continuing service: one-sixth of the shares subject to the inducement RSU award shall vest on the first trading day on or after each of February 28, 2027, August 31, 2027, February 29, 2028, August 31, 2028, February 28, 2029, and August 31, 2029.

Each inducement award is subject to the terms of the RxSight, Inc. 2026 Inducement Equity Incentive Plan and related forms of agreements, and were granted as inducements material to these employees to enter into employment with RxSight in accordance with Nasdaq Listing Rule 5635(c)(4).

About RxSight, Inc.

RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The Light Adjustable Lens™ system, comprised of the RxSight Light Adjustable Lens™ products (LAL™ and LAL+™), RxSight Light Delivery Device™ (LDD™), and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.

Light Adjustable Lens™, LAL™, LAL+™, Light Delivery Device™ and LDD™ are trademarks of RxSight, Inc.

Investor Relations Contact: Oliver Moravcevic VP, Investor Relations [email protected]

Oct 20, 2026

Download PDF

ALISO VIEJO, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- **(NASDAQ: RXST) –**RxSight, Inc., today announced that it will report financial results for the third quarter of 2026 after the market close on Tuesday, November 3, 2026. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

To participate in the conference call, please dial (800) 715-9871 or (646) 307-1963 and enter the conference code: 8782462. The call will also be broadcast live in listen-only mode via a link on the company’s investor relations website at https://investors.rxsight.com/. An archived recording of the call will be available through the same link shortly after its completion.

About RxSight, Inc.

RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The Light Adjustable Lens™ system, comprised of the RxSight Light Adjustable Lens™ products (LAL™ and LAL+™), RxSight Light Delivery Device™ (LDD™), and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.

Investor Relations Contact: Oliver Moravcevic VP, Investor Relations [email protected]

Prompts

RxSight, Inc. (ticker RXST), listed in United States.

Company History

Date Change Detail
Mar 8, 2017 Renamed CALHOUN VISION INC → RXSIGHT, INC.

ETFs Holding RxSight, Inc.

ETF Weight in ETF Shares Market value As of
AVSC 0.01% 33,407 $ 177.057K Nov 16, 2026
RESM 0.01% 67 $ 322.94 Jun 30, 2026
DFAS 0.00% 29,061 $ 156.348K Nov 12, 2026